{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:21:49Z","timestamp":1790043709273,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15SA0018404"],"award-info":[{"award-number":["NNF15SA0018404"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15SA0018404"],"award-info":[{"award-number":["NNF15SA0018404"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol\/bisoprolol\/nebivolol should be preferred over carvedilol. However, studies suggest a high proportion of carvedilol usage that remains unexplained. Therefore, we aimed to investigate the predictors of carvedilol choice in patients with heart failure and COPD that were na\u00efve to carvedilol or metoprolol\/bisoprolol\/nebivolol. Caserta Local Health Unit databases (Italy) were used as data sources. Age, sex, chronic\/acute comorbidities, and co-medications were included in a logistic regression model to assess predictors of carvedilol choice. Chronic comorbidities include those defined in the Elixhauser comorbidity index and all hospitalizations within two years prior to the first beta-blocker prescription. Comedications include all redeemed prescriptions within one year prior to the beta-blocker prescription. Kernel density estimations were used to assess the overlap in propensity and preference scores distributions for receiving carvedilol and thereby potential beta-blocker exchangeability. Totally, 10091 patients composed the study population; 2011 were exposed to carvedilol. The overlapping of propensity scores distributions was 57%. Accordingly, the exchangeability was not reached. Atrioventricular block (Odds Ratio, <jats:italic>OR<\/jats:italic> 8.20; 95% Confidence Interval, 95% <jats:italic>CI<\/jats:italic> 1.30\u201351.80), cerebrovascular thrombosis (OR 7.06; 95% CI 1.14\u201343.68), chronic kidney disease (OR 4.32; 95% CI 1.16\u201316.02), and acute heart failure (OR 1.97; 95% CI 1.28\u20133.03) hospitalizations were statistically significantly associated with carvedilol choice. Analogously, human insulin (OR 3.00; 95% CI 1.24\u20137.24), fondaparinux (OR 2.47; 95% CI 1.17\u20135.21) or strontium ranelate (OR 2.03; 95% CI 1.06\u20133.90) redeemed prescriptions. In conclusion, this study suggests the absence of beta-blockers exchangeability and a preferential choice of carvedilol in patients with heart failure, COPD and concurrent chronic kidney disease, atrioventricular block, cerebrovascular thrombosis, acute heart failure or redeeming human insulin, fondaparinux or strontium ranelate prescriptions. Therefore, it suggests that choice of prescribing carvedilol over metoprolol\/bisoprolol\/nebivolol is driven by differences in comorbidities and co-treatments.<\/jats:p>","DOI":"10.1038\/s41598-019-47967-y","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T10:02:56Z","timestamp":1565172176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-4744","authenticated-orcid":false,"given":"Maurizio","family":"Sessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Bech","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Kragholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus Thorsten","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberata","family":"Sportiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Michele","family":"Tari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-2860","authenticated-orcid":false,"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"47967_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1183\/09031936.00133805","volume":"28","author":"DD Sin","year":"2006","unstructured":"Sin, D. D., Anthonisen, N. R., Soriano, J. B. & Agusti, A. G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 28, 1245\u20131257 (2006).","journal-title":"Eur. Respir. J."},{"key":"47967_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fphys.2013.00240","volume":"4","author":"A Lymperopoulos","year":"2013","unstructured":"Lymperopoulos, A. Physiology and pharmacology of the cardiovascular adrenergic system. Front. Physiol. 4, 240 (2013).","journal-title":"Front. Physiol."},{"key":"47967_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.maturitas.2016.03.022","volume":"93","author":"G Santulli","year":"2016","unstructured":"Santulli, G. & Iaccarino, G. Adrenergic signaling in heart failure and cardiovascular aging. Maturitas 93, 65\u201372 (2016).","journal-title":"Maturitas"},{"key":"47967_CR4","first-page":"394","volume":"5","author":"R Hatton","year":"2015","unstructured":"Hatton, R., Cvjeticanin, A. & Lymperopoulos, A. The adrenergic system of the adrenal glands as a remote control of cardiac function. J Cardiovasc Dis 5, 394\u2013397 (2015).","journal-title":"J Cardiovasc Dis"},{"key":"47967_CR5","doi-asserted-by":"crossref","unstructured":"Ciccarelli, M., Sorriento, D., Coscioni, E., Iaccarino, G. & Santulli, G. Adrenergic receptors. In Endocrinology of the Heart in Health and Disease 285\u2013315 (Elsevier, 2017).","DOI":"10.1016\/B978-0-12-803111-7.00011-7"},{"key":"47967_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-15961-4_5","volume-title":"Pathophysiology and Pharmacotherapy of Cardiovascular Disease","author":"Gaetano Santulli","year":"2015","unstructured":"Santulli, G. Sympathetic Nervous System Signaling in Heart Failure and Cardiac Aging BT - Pathophysiology and Pharmacotherapy of Cardiovascular Disease. in (eds Jagadeesh, G., Balakumar, P. & Maung-U, K.) 83\u2013105, https:\/\/doi.org\/10.1007\/978-3-319-15961-4_5 (Springer International Publishing, 2015)."},{"key":"47967_CR7","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.2147\/COPD.S144333","volume":"12","author":"KP Lim","year":"2017","unstructured":"Lim, K. P., Loughrey, S., Musk, M., Lavender, M. & Wrobel, J. P. Beta-blocker under-use in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 3041\u20133046 (2017).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"47967_CR8","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.mayocp.2018.05.026","volume":"93","author":"S Mirza","year":"2018","unstructured":"Mirza, S., Clay, R. D., Koslow, M. A. & Scanlon, P. D. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin. Proc. 93, 1488\u20131502 (2018).","journal-title":"Mayo Clin. Proc."},{"key":"47967_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of. Eur. Heart J. 37, 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"key":"47967_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ejhf.1045","volume":"20","author":"M Sessa","year":"2018","unstructured":"Sessa, M. et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur. J. Heart Fail. 20, 548\u2013556 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"47967_CR11","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2010.01.024","volume":"55","author":"A Jabbour","year":"2010","unstructured":"Jabbour, A. et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J. Am. Coll. Cardiol. 55, 1780\u20131787 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"47967_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3389\/fphar.2018.01212","volume":"9","author":"M Sessa","year":"2018","unstructured":"Sessa, M. et al. Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different beta1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. Front. Pharmacol. 9, 1212 (2018).","journal-title":"Front. Pharmacol."},{"key":"47967_CR13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.chest.2018.01.008","volume":"153","author":"F Maltais","year":"2018","unstructured":"Maltais, F. et al. Beta-Blockers in COPD: A Cohort Study From the TONADO Research Program. Chest 153, 1315\u20131325 (2018).","journal-title":"Chest"},{"key":"47967_CR14","first-page":"1b","volume":"10","author":"JH Garvin","year":"2013","unstructured":"Garvin, J. H. et al. Exploration of ICD-9-CM coding of chronic disease within the Elixhauser Comorbidity Measure in patients with chronic heart failure. Perspect. Heal. Inf. Manag. 10, 1b (2013).","journal-title":"Perspect. Heal. Inf. Manag."},{"key":"47967_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/ije\/15.3.413","volume":"15","author":"S Greenland","year":"1986","unstructured":"Greenland, S. & Robins, J. M. Identifiability, exchangeability, and epidemiological confounding. Int. J. Epidemiol. 15, 413\u2013419 (1986).","journal-title":"Int. J. Epidemiol."},{"key":"47967_CR16","first-page":"11","volume":"3","author":"AM Walker","year":"2013","unstructured":"Walker, A. M. et al. A tool for assessing the feasibility of comparative effectiveness research. Comp. Eff. Res. 3, 11\u201320 (2013).","journal-title":"Comp. Eff. Res."},{"key":"47967_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","volume":"70","author":"GL Bakris","year":"2006","unstructured":"Bakris, G. L., Hart, P. & Ritz, E. Beta blockers in the management of chronic kidney disease. Kidney Int. 70, 1905\u20131913 (2006).","journal-title":"Kidney Int."},{"issue":"Suppl 2","key":"47967_CR18","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1007\/BF01409488","volume":"38","author":"T Takeda","year":"1990","unstructured":"Takeda, T. et al. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. Eur. J. Clin. Pharmacol. 38(Suppl 2), S158\u201363 (1990).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"47967_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.5414\/CNP57352","volume":"57","author":"M Nowicki","year":"2002","unstructured":"Nowicki, M., Szewczyk-Seifert, G., Klimek, D. & Kokot, F. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin. Nephrol. 57, 352\u2013358 (2002).","journal-title":"Clin. Nephrol."},{"key":"47967_CR20","doi-asserted-by":"publisher","first-page":"e000230","DOI":"10.1136\/openhrt-2014-000230","volume":"2","author":"JJ DiNicolantonio","year":"2015","unstructured":"DiNicolantonio, J. J. et al. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Hear. 2, e000230 (2015).","journal-title":"Open Hear."},{"key":"47967_CR21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","volume":"292","author":"GL Bakris","year":"2004","unstructured":"Bakris, G. L. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292, 2227\u20132236 (2004).","journal-title":"JAMA"},{"key":"47967_CR22","doi-asserted-by":"publisher","first-page":"e5070","DOI":"10.1097\/MD.0000000000005070","volume":"95","author":"K-M Liao","year":"2016","unstructured":"Liao, K.-M., Liang, F.-W. & Li, C.-Y. Risks of all-cause and site-specific fractures among hospitalized patients with COPD. Medicine (Baltimore). 95, e5070\u2013e5070 (2016).","journal-title":"Medicine (Baltimore)."},{"key":"47967_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1359\/JBMR.041202","volume":"20","author":"IR Reid","year":"2005","unstructured":"Reid, I. R. et al. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. 20, 613\u2013618 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"47967_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00223-006-0213-1","volume":"80","author":"F de Vries","year":"2007","unstructured":"de Vries, F., Souverein, P. C., Cooper, C., Leufkens, H. G. M. & van Staa, T. P. Use of beta-blockers and the risk of hip\/femur fracture in the United Kingdom and The Netherlands. Calcif. Tissue Int. 80, 69\u201375 (2007).","journal-title":"Calcif. Tissue Int."},{"key":"47967_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0092-8674(02)01049-8","volume":"111","author":"S Takeda","year":"2002","unstructured":"Takeda, S. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111, 305\u2013317 (2002).","journal-title":"Cell"},{"key":"47967_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3163\/1536-5050.104.4.007","volume":"104","author":"RI Patel","year":"2016","unstructured":"Patel, R. I. & Beckett, R. D. Evaluation of resources for analyzing drug interactions. J. Med. Libr. Assoc. 104, 290\u2013295 (2016).","journal-title":"J. Med. Libr. Assoc."},{"key":"47967_CR27","first-page":"4208","volume":"39","author":"A Alatri","year":"2017","unstructured":"Alatri, A. et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur. Heart J. 39, 4208\u20134218 (2017).","journal-title":"Eur. Heart J."},{"key":"47967_CR28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","volume":"40","author":"M Metra","year":"2002","unstructured":"Metra, M. et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. 40, 1248\u20131258 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"key":"47967_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/heart.89.6.621","volume":"89","author":"E Bollano","year":"2003","unstructured":"Bollano, E., Tang, M. S., Hjalmarson, A., Waagstein, F. & Andersson, B. Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart 89, 621\u2013624 (2003).","journal-title":"Heart"},{"key":"47967_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2006.10.007","volume":"252","author":"T Dziedzic","year":"2007","unstructured":"Dziedzic, T., Slowik, A., Pera, J. & Szczudlik, A. Beta-blockers reduce the risk of early death in ischemic stroke. J. Neurol. Sci. 252, 53\u201356 (2007).","journal-title":"J. Neurol. Sci."},{"key":"47967_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1097\/00004647-200008000-00005","volume":"20","author":"SI Savitz","year":"2000","unstructured":"Savitz, S. I. et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J. Cereb. Blood Flow Metab. 20, 1197\u20131204 (2000).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"47967_CR32","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1161\/01.STR.23.11.1630","volume":"23","author":"PG Lysko","year":"1992","unstructured":"Lysko, P. G. et al. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 23, 1630\u20131636 (1992).","journal-title":"Stroke"},{"key":"47967_CR33","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ejheart.2007.07.014","volume":"9","author":"WJ Remme","year":"2007","unstructured":"Remme, W. J. et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur. J. Heart Fail. 9, 1128\u20131135 (2007).","journal-title":"Eur. J. Heart Fail."},{"key":"47967_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1388-9842(01)00126-X","volume":"3","author":"K Stoschitzky","year":"2001","unstructured":"Stoschitzky, K. et al. Differing beta-blocking effects of carvedilol and metoprolol. Eur. J. Heart Fail. 3, 343\u2013349 (2001).","journal-title":"Eur. J. Heart Fail."},{"key":"47967_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000093060","volume":"106","author":"K Stoschitzky","year":"2006","unstructured":"Stoschitzky, K., Stoschitzky, G., Brussee, H., Bonelli, C. & Dobnig, H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 106, 199\u2013206 (2006).","journal-title":"Cardiology"},{"key":"47967_CR36","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fphar.2018.00844","volume":"9","author":"M Sessa","year":"2018","unstructured":"Sessa, M. et al. Relationship Between Gender and the Effectiveness of Montelukast: An Italian\/Danish Register-Based Retrospective Cohort Study. Front. Pharmacol. 9, 844 (2018).","journal-title":"Front. Pharmacol."},{"key":"47967_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2017.00305","volume":"8","author":"M Sessa","year":"2017","unstructured":"Sessa, M. et al. Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs\u2019 Adverse Drug Reactions. Frontiers in Pharmacology 8, 305 (2017).","journal-title":"Frontiers in Pharmacology"},{"key":"47967_CR38","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/COPD.S145913","volume":"12","author":"YL Huang","year":"2017","unstructured":"Huang, Y. L. et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 2987\u20132996 (2017).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"47967_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.107.704023","volume":"118","author":"JA Johnson","year":"2008","unstructured":"Johnson, J. A. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation 118, 1383\u20131393 (2008).","journal-title":"Circulation"},{"key":"47967_CR40","unstructured":"Italian National Institute of Statistics. [Cittadini Stranieri. Popolazione residente e bilancio demografico al 31 dicembre 2018 (dati provvisori) Comune: Caserta], https:\/\/www.istat.it\/en\/ (2019). Available at, http:\/\/demo.istat.it\/str2018\/query.php?Rip=S4&Reg=R15&Pro=P061&Com=22&paese=A9999. (Accessed: 8th July 2019)."},{"key":"47967_CR41","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2217\/pgs-2018-0115","volume":"19","author":"BM Parker","year":"2018","unstructured":"Parker, B. M., Rogers, S. L. & Lymperopoulos, A. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle. Pharmacogenomics 19, 1089\u20131093 (2018).","journal-title":"Pharmacogenomics"},{"key":"47967_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1389200217666151105125425","volume":"17","author":"A Lymperopoulos","year":"2015","unstructured":"Lymperopoulos, A., McCrink, K. A. & Brill, A. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol. Curr. Drug Metab. 17, 30\u201336 (2015).","journal-title":"Curr. Drug Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47967-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:26:26Z","timestamp":1671279986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47967-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["47967"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-47967-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. Morten Andersen has participated in research projects funded by AstraZeneca, H. Lundbeck & Mertz, Novartis, Pfizer and Janssen, with grants paid to the institutions where he has been employed, and has personally received fees from Medicademy, the Danish Pharmaceutical Industry Association, for leading and teaching pharmacoepidemiology courses. Other authors have no conflicts of interest that are directly relevant to the contents of this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11465"}}